Citius Oncology (CTOR) Research & Development (2023 - 2026)

Citius Oncology (CTOR) has 4 years of Research & Development data on file, last reported at $1.1 million in Q1 2026.

• On a quarterly basis, Research & Development fell 65.62% year-over-year to $1.1 million in Q1 2026; TTM through Mar 2026 was $8.0 million, a 4.4% decrease from a year earlier, with the FY2025 full-year figure at $6.4 million, up 226.86% from the prior year.
• Research & Development for Q1 2026 stood at $1.1 million, up from $1.0 million in the prior quarter.
• Over the last five years, Research & Development for CTOR reached as high as $5.0 million in Q3 2025 and fell as low as $483063.0 in Q4 2023.
• Historically, Research & Development has averaged $1.9 million across 4 years, with a median of $1.3 million in 2024.
• Across the five-year window, Research & Development jumped 161.77% in 2024 and sank 65.62% in 2026, its largest moves.
• Year by year, Research & Development stood at $483063.0 in 2023, then soared by 161.77% to $1.3 million in 2024, then retreated by 19.47% to $1.0 million in 2025, then increased by 5.99% to $1.1 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $1.1 million in Q1 2026, $1.0 million in Q4 2025, and $5.0 million in Q3 2025.